Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETRAIN: OM-89 vs Placebo for UTI Prevention in Neurogenic Bladder
NCT06588010Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Dec 2024
- Primary completion
- Dec 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of OM-89 in urinary tract infection (UTI) (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Number of antibiotic treatment episodes for UTIs per person-days at risk at 12 months. Started Dec 2024; status: recruiting.
02
Drugs
OM-89
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT06588010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588010.